KRAS and neoplasm: These include the CPP19 and CPP30 cell lines that have been freshly established from liver metastasis biopsies that express mutated KRAS and wild‐type KRAS/BRAF, respectively, and the CTC44 and CTC45 cell lines derived from circulating tumour cells (CTC) that express mutated BRAF from two chemotherapy‐naive patients with metastatic CRC (stage IV).